Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Braze Inc (BRZE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Braze Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Braze Inc trades at $23.86 (market cap $2.75B). The key difference: ACADIA Pharmaceuticals Inc. is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Braze Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | BRZE | |
|---|---|---|
Market Cap | $4.49B | $2.75B |
Sector | Health | Technology |
52-Week High | $28.06 | $36.19 |
52-Week Low | $20.06 | $15.79 |
Enterprise Value | $3.69B | $2.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Braze (BRZE) trades at $24.40, up 2.48% on the day, with a bullish technical outlook and strong analyst support. Revenue growth accelerated to 30% year-over-year in Q1 2027, though the company remains unprofitable with a net income margin of -15.51%. Recent news highlights AI-driven product enhancements and robust customer engagement demand, contributing to positive sentiment despite recent earnings misses relative to expectations.
The investment case hinges on sustained revenue acceleration and path to profitability, supported by a 96% buy rating from analysts and a $34.78 consensus price target. Key risks include persistent losses, competitive pressures in customer engagement software, and sensitivity to enterprise marketing budgets. Upside potential exists if AI adoption drives further growth and margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Braze Inc
Braze Inc is a customer engagement platform that powers customer-centric interactions between consumers and brands. The company provides solutions for Retail & E-commerce, Media & Entertainment, Financial Services, and Travel & Hospitality related industries.
Read more on BRZE →
